17:50 , Jun 28, 2018 |  BC Innovations  |  Distillery Therapeutics

Endocrine/Metabolic

INDICATION: Obesity Mouse studies suggest inhibiting IDO could help treat obesity. In a mouse model of high-fat diet-induced obesity, systemic IDO knockout decreased white adipose tissue (WAT), liver and body weights, lipid levels in the liver...
19:07 , May 18, 2018 |  BC Week In Review  |  Company News

Genentech terminates NewLink collaboration for IDO, TDO inhibitors

NewLink Genetics Corp. (NASDAQ:NLNK) said in an SEC filing that the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) terminated the remaining portion of a 2014 research collaboration that covered the development of next-generation indoleamine 2,3-dioxygenase...
23:45 , Apr 20, 2018 |  BioCentury  |  Product Development

Lessons from the ECHO chamber

Lessons from the failure of ECHO-301 go beyond the prospects of combining IDO1 and PD-1 inhibition to treat cancer. The broader concern is for the gamut of Phase I/II trials testing PD-1 combinations, many of...
18:30 , Apr 20, 2018 |  BC Week In Review  |  Clinical News

NewLink re-evaluating Phase III plans for indoximod combo in melanoma

NewLink Genetics Corp. (NASDAQ:NLNK) said it will not start the randomized, placebo-controlled portion of the Phase III Indigo301 trial to evaluate indoximod (NLG8189) plus anti-PD-1 mAbs Keytruda pembrolizumab or Opdivo nivolumab to treat unresectable or...
21:26 , Apr 16, 2018 |  BC Extra  |  Clinical News

NewLink re-evaluating Phase III plans for indoximod combo

NewLink Genetics Corp. (NASDAQ:NLNK) said Sunday that it will not start the randomized, placebo-controlled portion of the Phase III Indigo301 trial to evaluate indoximod (NLG8189) plus anti-PD-1 mAbs Keytruda pembrolizumab or Opdivo nivolumab to treat...
14:26 , Apr 6, 2018 |  BC Extra  |  Clinical News

Incyte tumbles after epacadostat miss

Incyte Corp. (NASDAQ:INCY) fell $19.05 (23%) to $64.02 on Friday after the company and partner Merck & Co. Inc. (NYSE:MRK) said epacadostat plus Merck’s anti-PD-1 mAb Keytruda pembrolizumab missed the primary endpoint in the Phase...
22:01 , Jan 2, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious Disease

INDICATION: Tuberculosis Cell culture and macaque studies suggest inhibiting IDO could help treat tuberculosis (TB). In a co-culture of Mycobacterium tuberculosis-infected macaque macrophages and M. tuberculosis-specific macaque CD4+ T cells, siRNA targeting IDO1 decreased bacterial burden...
00:05 , Dec 20, 2017 |  BC Extra  |  Preclinical News

Inhibiting IDO could slow TB disease progression

In a paper published in the Proceedings of the National Academy of Sciences, researchers at Tulane University School of Medicine and colleagues found that inhibiting indoleamine 2,3-dioxygenase (IDO; INDO) could slow tuberculosis disease progression, suggesting...
16:54 , Oct 6, 2017 |  BC Week In Review  |  Financial News

NewLink, Strongbridge price follow-ons

NewLink Genetics Corp. (NASDAQ:NLNK) and Strongbridge Biopharma plc (NASDAQ:SBBP) each priced follow-ons, raising more than $75 million. On Oct. 3, NewLink raised $51.3 million through the sale of 5 million shares at $10.25 in a bumped-up...
21:14 , Oct 4, 2017 |  BC Extra  |  Financial News

NewLink, Strongbridge price follow-ons

NewLink Genetics Corp. (NASDAQ:NLNK) and Strongbridge Biopharma plc (NASDAQ:SBBP) each priced follow-ons, raising more than $75 million. NewLink raised $51.3 million through the sale of 5 million shares at $10.25 in a bumped-up follow-on underwritten by...